AFFIX Labs
With a headquarter in Helsinki, Finland, Affix Labs has years of success with their other products focusing on fighting against insect-borne diseases such as Malaria, Dengue and Zika viruses. Their proprietary technology focuses on binding safe chemicals in a way that boosts their effectiveness and longevity.
Affix Labs Oy
P.O. Box 176
00101 Helsinki
Finland
+358 9 8561 7167
www.affixlabs.com
info@affixlabs.com
3 Aug 2020
Tests confirm new long-lasting surface coating for public spaces proven to kill COVID-19
Leading chemical binding expert AFFIX Labs has harnessed its global experience in disease prevention to create the first long-lasting surface treatment proven to kill the coronavirus (COVID-19). Now available in Europe and the UAE and launching in new global markets, the surface treatment, known as Si-Quat, combines a safe and well-established disinfectant with the lab’s proprietary chemical binding technique.
20 Jul 2020
AFFIX Labs launches world’s first long-lasting surface treatment to kill the coronavirus
Leading chemical binding expert AFFIX Labs has harnessed its global experience in disease prevention to create the first long-lasting surface treatment proven to kill COVID-19. Si-Quat combines a safe and well-established disinfectant and a proprietary chemical binding technique, so that the active ingredient can kill viruses, including SARS-COV-2. Testing at Portugal’s Biochemistry Institute at the University of Lisbon proves that Si-Quat effectively kills the COVID-19 pathogens that it comes into contact with.